Management of SSRI-Induced Sleep Bruxism
The first-line intervention for SSRI-induced sleep bruxism is adding buspirone 5–10 mg twice daily, which resolves symptoms in most patients within 3–4 weeks by restoring dopaminergic tone suppressed by serotonergic excess. 1, 2, 3
Understanding the Mechanism
SSRIs trigger bruxism through mesocortical serotonergic disinhibition that depletes dopamine in extrapyramidal pathways controlling masticatory muscle activity. 3 This represents a specific form of akathisia rather than a primary sleep disorder. 3 The phenomenon occurs in both pediatric and adult patients, with female patients disproportionately affected. 1 Fluoxetine, sertraline, and venlafaxine are the most commonly implicated agents. 1, 4
Symptoms typically emerge within 3–4 weeks of SSRI initiation and can develop with both short-term and long-term antidepressant use. 1 The bruxism frequency is strikingly high—73.3% of patients on antidepressants versus 28.2% of controls in one study—with SSRIs like escitalopram and sertraline being the primary offenders. 4
Treatment Algorithm
Step 1: Add Buspirone (Preferred First-Line)
Add buspirone 5 mg twice daily, titrating to 10 mg twice daily if needed after one week. 2, 3 Buspirone acts as a full agonist at presynaptic 5-HT1A somatodendritic receptors on raphe serotonergic neurons projecting to the ventral tegmental area, thereby modulating the mesocortical tract that inhibits spontaneous masticatory movements. 3 This dual mechanism—reducing serotonergic activity while increasing dopaminergic activity—directly counteracts the SSRI-induced dopamine depletion. 2, 3
Expect symptom resolution within 3–4 weeks of buspirone initiation. 1 Four published case series demonstrate consistent efficacy across pediatric and adult populations. 2, 3 Buspirone does not compromise the antidepressant efficacy of the SSRI and carries minimal risk of adverse effects. 3
Step 2: Alternative Pharmacologic Options (If Buspirone Fails or Is Contraindicated)
If buspirone is ineffective after 4 weeks or not tolerated:
Low-dose quetiapine 25–50 mg nightly can improve SSRI-induced bruxism through 5-HT2 receptor antagonism. 5 Five patients treated with this regimen reported complete resolution of bruxism within days. 5 However, quetiapine carries metabolic risks (weight gain, hyperglycemia, dyslipidemia) and is explicitly not recommended by the American Academy of Sleep Medicine for primary insomnia. 6 Use only when buspirone has failed and the patient cannot tolerate SSRI discontinuation or substitution.
Clonazepam showed significant reductions in specific sleep bruxism parameters in systematic review, though several side effects were reported. 7 The American Academy of Sleep Medicine recommends clonazepam 0.5–1 mg at bedtime for REM sleep behavior disorder, noting that SSRIs can induce or exacerbate this condition. 8 However, benzodiazepines carry risks of dependence, falls, cognitive impairment, and respiratory depression, particularly in older adults. 8, 6
Step 3: SSRI Dose Reduction or Substitution
If buspirone and alternative agents fail, reduce the SSRI dose by 25–50% or switch to a non-serotonergic antidepressant. 1 Symptoms typically resolve within 3–4 weeks of dose modification or drug discontinuation. 1
Consider switching to:
- Mirtazapine 7.5–30 mg at bedtime, which promotes sleep and has minimal bruxism risk due to its histamine H1 antagonism rather than serotonergic excess. 9, 10 Lower doses (7.5 mg) are more sedating. 9
- Bupropion (if insomnia is not a concern), which has dopaminergic and noradrenergic activity without serotonergic effects. 9 However, bupropion should not be used if insomnia is present, and the second dose must be given before 3 p.m. 9
Step 4: Non-Pharmacologic Interventions
Initiate Cognitive Behavioral Therapy for Insomnia (CBT-I) concurrently with pharmacologic management. 6, 10 CBT-I provides superior long-term efficacy for sleep disturbances and should include stimulus control, sleep restriction, and cognitive restructuring. 6 Sleep hygiene education alone is insufficient. 6
Consider biofeedback therapy (BFT), which showed significant reductions in specific sleep bruxism parameters in systematic review. 7 BFT trains patients to recognize and reduce masticatory muscle tension through real-time electromyographic feedback.
Oral appliance therapy (OAT) with stabilization splints tends to reduce the number of sleep bruxism events, though evidence does not show significant superiority over other splint types. 7 This protects dentition from damage but does not address the underlying SSRI-induced mechanism.
Critical Safety Considerations
Do not combine multiple sedating agents (e.g., adding clonazepam to quetiapine or an SSRI) without careful monitoring, as this markedly increases risks of respiratory depression, cognitive impairment, falls, and complex sleep behaviors. 8, 6
Monitor for serotonin syndrome when adding buspirone to an SSRI, particularly during the first 24–48 hours. 8 Symptoms include mental status changes (confusion, agitation), neuromuscular hyperactivity (tremor, clonus, hyperreflexia), and autonomic hyperactivity (hypertension, tachycardia, diaphoresis). 8 However, the risk is substantially lower with buspirone than with MAOIs or when combining multiple serotonergic agents. 8
Reassess bruxism severity and sleep quality after 2–4 weeks of any intervention to evaluate efficacy and detect adverse effects. 10, 1
Common Pitfalls to Avoid
Failing to recognize SSRI-induced bruxism as a medication side effect rather than a primary sleep disorder leads to inappropriate treatment with hypnotics instead of addressing the underlying dopaminergic depletion. 1, 3
Prescribing trazodone for SSRI-induced insomnia is discouraged because it provides only minimal sleep benefit (~10 minutes reduction in sleep latency) with no improvement in subjective sleep quality, and adverse events occur in ~75% of older adults. 6
Using over-the-counter antihistamines (diphenhydramine, doxylamine) is contraindicated due to lack of efficacy, strong anticholinergic effects (confusion, urinary retention, falls), and rapid tolerance development within 3–4 days. 6, 10
Discontinuing the SSRI abruptly without tapering can precipitate withdrawal symptoms including rebound anxiety and insomnia. 9 Taper over 10–14 days if discontinuation is necessary. 9
Ignoring the association between bruxism and poor sleep quality—patients with bruxism have significantly higher Pittsburgh Sleep Quality Index scores and excessive daytime sleepiness. 4 Address both the bruxism and the underlying sleep disturbance concurrently.